CMR Surgical :: Versius Surgical Robotic System

CMR Surgical is a British medical technology company founded in 2014 and headquartered in Cambridge, United Kingdom. The company develops and commercializes the Versius Surgical Robotic System, a next-generation robotic platform designed to make robotic-assisted minimally invasive surgery more accessible to hospitals and surgeons worldwide. CMR Surgical’s mission is to “transform surgery for good” by addressing key barriers to adoption — such as high costs, large footprints, and limited flexibility — through a compact, modular, and portable design. The company has a strong global presence and is rapidly expanding, particularly in the United States following recent regulatory milestones.

The Versius Plus system is CMR Surgical’s flagship robotic platform. It is engineered for versatility and adaptability across multiple surgical specialties and care settings.

Key Features of Versius Plus:

• Modular & Portable Design: Unlike traditional large robotic systems, Versius Plus consists of independent, compact robotic arms that can be easily moved between operating rooms. No dedicated OR is required, allowing hospitals to switch seamlessly between robotic and laparoscopic procedures.
• Versatile Port Placement: Surgeons can choose optimal port configurations based on patient anatomy and preferred surgical technique, leveraging their existing laparoscopic skills.
• Advanced Vision System: Integrated fluorescence imaging (vLimeLite) with real-time ICG visualization provides enhanced visual information during procedures.
• Digitally Driven Ecosystem: Includes dedicated apps — Versius Connect for surgeons (procedural logbook and insights) and Versius Team for hospital teams (live dashboards for usage and efficiency tracking).
• Full Suite of Instruments: Supports a wide range of laparoscopic instruments for various procedures.

As of early 2026, Versius has been used in over 45,000 procedures globally, making it the second most utilized robotic surgical platform worldwide. The system recently received FDA 510(k) clearance for cholecystectomy in the United States, with a submission filed for benign gynecologic indications. It is already widely used in Europe, Asia, and other regions for general surgery, gynecology, thoracic, and urologic procedures.

CMR Surgical continues to focus on expanding clinical evidence, improving digital capabilities, and increasing global access to robotic surgery through its adaptable and cost-effective platform.